We are live on ! Find out more
KALV

KalVista Pharmaceuticals
KALV

Delisted

KALV was delisted on the 10th of June, 2026.

Back to rankings

1 hedge funds and large institutions have $189 invested in KalVista Pharmaceuticals in 2026 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 181 closing their positions.

New
Increased
Maintained
Reduced
Closed

99% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 181

99% less funds holding

Funds holding: 184 → 1 (-183)

100% less funds holding in top 10

Funds holding in top 10: 9 → 0 (-9)

100% less capital invested

Capital invested by funds: $1.39B → $189 (-$1.39B)

130.07% less ownership

Funds ownership: 130.07% → 0% (-130%)

Holders
1
Holders Change
-183
Holders Change %
-99.46%
% of All Funds
0.01%
Holding in Top 10
–
Holding in Top 10 Change
-9
Holding in Top 10 Change %
-100%
% of All Funds
–
New
1
Increased
–
Reduced
–
Closed
181
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
IA
IFP Advisors
Florida
+$169

Top Sellers

Rank Fund Capital Flow
1
VA
VR Adviser
New York
-$130M
2
FLSM
Frazier Life Sciences Management
California
-$99.9M
3
SCM
Suvretta Capital Management
New York
-$96M
4
TCM
Tang Capital Management
California
-$92.1M
5
BlackRock
BlackRock
New York
-$76.4M

KALV Hedge Fund Activity: Q2 2026 in Review

1 of the 8,329 institutional investors tracked by Wall St. Rank reported a position in KalVista Pharmaceuticals (KALV) for Q2 2026, worth a combined $189 — down 100% from $1.39B a quarter earlier.

Sellers outnumbered buyers: 181 funds closed out of KALV and 1 opened new positions — a net loss of 180 holders — while 0 trimmed existing stakes and 0 added.

The largest buyer was IFP Advisors, opening a new position worth an estimated $169. The largest seller was VR Adviser, exiting entirely with an estimated $130M sold.

  • 1 institutional investor held KalVista Pharmaceuticals (KALV) as of Q2 2026, down from 184 in Q1 2026.
  • Funds reported $189 of KalVista Pharmaceuticals stock for Q2 2026, down 100% quarter-over-quarter.
  • 1 fund opened new KalVista Pharmaceuticals positions in Q2 2026 and 181 closed out, a net change of -180 holders.
  • The largest KalVista Pharmaceuticals buyer in Q2 2026 was IFP Advisors, an estimated $169 added.
  • The largest KalVista Pharmaceuticals seller in Q2 2026 was VR Adviser, an estimated $130M sold.

Based on aggregated 13F filings for Q2 2026.